HE 2200

Drug Profile

HE 2200

Alternative Names: androstenetriol; Reversionex

Latest Information Update: 29 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virginia Commonwealth University
  • Developer Hollis-Eden Pharmaceuticals
  • Class Antihyperlipidaemics; Hormones
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Hypercholesterolaemia; Immunodeficiency disorders; Inflammatory bowel diseases; Multiple sclerosis; Neutropenia; Shock

Most Recent Events

  • 18 Aug 2003 Hollis-Eden has completed enrolment in a phase II trial for hypercholesterolaemia
  • 22 Apr 2003 Phase-II clinical trials in Immunodeficiency disorders in USA (SC)
  • 11 Mar 2003 HE 2200 is available for licensing (http://www.holliseden.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top